PT Millennium Pharmacon International Tbk Stocks

IDR 193Last Updated 28.04.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

IDR 14.68M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
IDR 193
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Millennium Pharmacon International Tbk engages in the distribution and trading of prescription and non-prescription medicines, dietary supplements, and medical devices in Indonesia. The company distributes its products through drug stores, pharmacies, hospitals, supermarkets, and retail shops. As of December 31, 2021, it operated 33 branch offices in Java, Bali, Sumatera, Kalimantan, and Sulawesi Islands. The company was formerly known as PT NVPD Soedarpo Corporation Tbk and changed its name to PT Millennium Pharmacon International Tbk in February 1990. The company was founded in 1952 and is headquartered in Jakarta Selatan, Indonesia. PT Millennium Pharmacon International Tbk is a subsidiary of Pharmaniaga International Corporation Sdn. Bhd.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks